blisibimod

Blisibimod is a recombinant fusion protein and selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS). It consists of four BAFF-binding domains fused to the Fc region of a human IgG1 antibody. Blisibimod binds with high affinity to all forms of BAFF, inhibiting its interaction with BAFF receptors and thereby reducing B-cell survival and proliferation. This mechanism targets the pathogenesis of several autoimmune diseases characterized by elevated BAFF levels, such as systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod was originally developed by Amgen and later acquired by Anthera Pharmaceuticals for further clinical development[1][4][5][6].

Brand names

blisibimod

Other names

blisibimod